Top

Breast Cancer Research and Treatment

Published in:

01-02-2013 | Letter to the Editor

A meta-regression analysis of the available data on adherence to adjuvant hormonal therapy in breast cancer: summarizing the data for clinicians

Authors: Laetitia Huiart, Cyril Ferdynus, Roch Giorgi

Published in: Breast Cancer Research and Treatment | Issue 1/2013

Excerpt

To the Editor, …

Murphy CC et al (2012) Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat 134(2):459–478PubMedCrossRef

van Houwelingen HC, Arends LR, Stijnen T (2002) Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med 21(4):589–624PubMedCrossRef

Guth U et al (2008) Target and reality of adjuvant endocrine therapy in postmenopausal patients with invasive breast cancer. Br J Cancer 99(3):428–433PubMedCrossRef

Guth U et al (2011) Drug switch because of treatment-related adverse side effects in endocrine adjuvant breast cancer therapy: How often and how often does it work? Breast Cancer Res Treat 129(3):799–807PubMedCrossRef

Rae JM et al (2009) Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients. Pharmacogenomics J 9(4):258–264PubMedCrossRef

Ishak KJ et al (2007) Meta-analysis of longitudinal studies. Clin Trials 4(5):525–539PubMedCrossRef

Klein JP et al (2007) Analyzing survival curves at a fixed point in time. Stat Med 26(24):4505–4519PubMedCrossRef

Viechtbauer W (2010) Conducting meta-analyses in R with the metafor package. J Stat Softw 36(3):1–48

McCowan C et al (2008) Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 99(11):1763–1768PubMedCrossRef

10.

Partridge AH et al (2008) Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 26(4):556–562PubMedCrossRef

11.

Kimmick G et al (2009) Adjuvant hormonal therapy use among insured, low-income women with breast cancer. J Clin Oncol 27(21):3445–3451PubMedCrossRef

12.

Hershman DL et al (2010) Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 28(27):4120–4128PubMedCrossRef

13.

Neugut AI et al (2011) Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol 29(18):2534–2542PubMedCrossRef

14.

Nekhlyudov L et al (2011) Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer. Breast Cancer Res Treat 130(2):681–689PubMedCrossRef

15.

Huiart L, Dell’Aniello S, Suissa S (2011) Use of tamoxifen and aromatase inhibitors in a large population-based cohort of women with breast cancer. Br J Cancer 104(10):1558–1563PubMedCrossRef

16.

Huiart L et al (2012) Early discontinuation of tamoxifen intake in younger women with breast cancer: Is it time to rethink the way it is prescribed? Eur J Cancer 48(13):1939–1946PubMedCrossRef

17.

Weaver KE, Camacho F, Hwang W, Anderson R, Kimmick G (2012) Adherence to adjuvant hormonal therapy and its relationship to breast cancer recurrence and survival among low-income women. Am J Clin Oncol. doi:10.1097/coc.0b013e3182436ec1

18.

Partridge AH et al (2003) Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21(4):602–606PubMedCrossRef

19.

Grunfeld EA et al (2005) Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Couns 59(1):97–102PubMedCrossRef

20.

Ma AM et al (2008) Noncompliance with adjuvant radiation, chemotherapy, or hormonal therapy in breast cancer patients. Am J Surg 196(4):500–504PubMedCrossRef

21.

Dezentje VO, van Blijderveen NJC, Gelderblom H, Putter H, van Herk-Sukel MPP, Casparie MK, Egberts ACG, Nortier JWR, Guchelaar H (2009) Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in earlystage breast cancer. J Clin Oncol 28(14):2423–2429

22.

Ziller V et al (2009) Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol 20(3):431–436PubMedCrossRef

23.

Sedjo RL, Devine S (2011) Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer. Breast Cancer Res Treat 125(1):191–200PubMedCrossRef

24.

Riley GF, Warren JL, Harlan LC, Blackwell SA (2011) Endocrine therapy use among elderly hormone receptor-positive breast cancer patients enrolled in Medicare Part D. Medicare Medicaid Res Rev 1(4):E1–E21. doi:10.5600/mmrr.001.04.a04

25.

Thompson AM et al (2011) Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Breast Cancer Res Treat 125(1):279–287PubMedCrossRef

26.

Wigertz A et al (2012) Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study. Breast Cancer Res Treat 133(1):367–373PubMedCrossRef

27.

Demissie S, Silliman RA, Lash TL (2001) Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol 19(2):322–328PubMed

28.

Fink AK et al (2004) Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. J Clin Oncol 22(16):3309–3315PubMedCrossRef

29.

Lash TL et al (2006) Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat 99(2):215–220PubMedCrossRef

30.

Kahn KL et al (2007) Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use. Med Care 45(5):431–439PubMedCrossRef

31.

Owusu C et al (2008) Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol 26(4):549–555PubMedCrossRef

32.

Schwartzberg LS et al (2009) Initial treatment and changes in adjuvant endocrine therapy for early stage breast cancer. Breast 18(2):78–83PubMedCrossRef

33.

van Herk-Sukel MP et al (2010) Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis. Breast Cancer Res Treat 122(3):843–851PubMedCrossRef

34.

Dittmer C et al (2011) Compliance to adjuvant therapy in breast cancer patients. Eur J Gynaecol Oncol 32(3):280–282PubMed

Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW (2012) Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat 134(2):459–478PubMedCrossRef

Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. (2012) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: a randomised trial. Lancet

Grunfeld EA, Hunter MS, Sikka P, Mittal S (2005) Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Couns 59:97–102PubMedCrossRef

Fink AK, Gurwitz J, Rakowski W, Guadagnoli E, Silliman RA (2004) Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. J Clin Oncol 22(16):3309–3315PubMedCrossRef

Kahn KL, Schneider EC, Malin JL, Adams JL, Epstein AM (2007) Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use. Med Care 45(5):431–439PubMedCrossRef

Huiart L, Bouknik A, Rey D, Tarpin C, Cluze C, Bendiane MK, Viens P, Giorgi R (2012) Early discontinuation of tamoxifen intake in younger women with breast cancer: is it time to rethink the way it is prescribed? Eur J Cancer 48(13):1939–1946PubMedCrossRef

Title: A meta-regression analysis of the available data on adherence to adjuvant hormonal therapy in breast cancer: summarizing the data for clinicians
Authors: Laetitia Huiart
Cyril Ferdynus
Roch Giorgi
Publication date: 01-02-2013
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2013
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-013-2422-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2013

Time-trends in survival in young women with breast cancer in a SEER population-based study

Cost-efficacy of acceleration partial-breast irradiation compared with whole-breast irradiation

Racial differences in outcomes of triple-negative breast cancer

Landscape and evolution of therapeutic research for breast cancer patients

Expression of key oestrogen-regulated genes differs substantially across the menstrual cycle in oestrogen receptor-positive primary breast cancer

Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology

Keynote webinar | Spotlight on antibody–drug conjugates in cancer